# Metoprolol ```text DRUG INFORMATION ADULT - (2) Hypertension: Starting dose is 25 to 100 mg. Source: US FDA label for metoprolol (metoprolol succinate), section 'dosage and administration', retrieved 2026-08-29 - (2.1) Angina Pectoris: Starting dose is 100 mg. Source: US FDA label for metoprolol (metoprolol succinate), section 'dosage and administration', retrieved 2026-08-29 - (2.2) Heart Failure: Starting dose is 12.5 or 25 mg. Source: US FDA label for metoprolol (metoprolol succinate), section 'dosage and administration', retrieved 2026-08-29 CHILD - One hundred forty-four hypertensive pediatric patients aged 6 to 16 years were randomized to placebo or to one of three dose levels of metoprolol succinate (0.2, 1 or 2 mg/kg once daily) and followed for 4 weeks. The study did not meet its primary endpoint (dose response for reduction in SBP). Some pre-specified secondary endpoints demonstrated effectiveness including: Dose-response for reduction in DBP, 1 mg/kg vs. Source: US FDA label for metoprolol (metoprolol succinate), section 'pediatric use', retrieved 2026-08-29 - Administer once daily. Titrate at weekly or longer intervals as needed and tolerated. (2) Hypertension: Starting dose is 25 to 100 mg. (2.1) Angina Pectoris: Starting dose is 100 mg. (2.2) Heart Failure: Starting dose is 12.5 or 25 mg. (2.3) Switching from immediate-release metoprolol to metoprolol succinate extended-release tablets: use the same total daily dose of metoprolol succinate extended-release tablets. Source: US FDA label for metoprolol (metoprolol succinate), section 'dosage and administration', retrieved 2026-08-29 - One hundred forty-four hypertensive pediatric patients aged 6 to 16 years were randomized to placebo or to one of three dose levels of metoprolol succinate (0.2, 1 or 2 mg/kg once daily) and followed for 4 weeks. Source: US FDA label for metoprolol (metoprolol succinate), section 'pediatric use', retrieved 2026-08-29 RENAL IMPAIRMENT - Therefore, initiate therapy at doses lower than those recommended for a given indication; and increase doses gradually in patients with impaired hepatic function. 8.7 Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Source: US FDA label for metoprolol (metoprolol succinate), section 'use in specific populations', retrieved 2026-08-29 HEPATIC IMPAIRMENT - Hepatic Impairment: Consider initiating metoprolol succinate therapy at low doses and gradually increase dosage to optimize therapy, while monitoring closely for adverse events. Source: US FDA label for metoprolol (metoprolol succinate), section 'use in specific populations', retrieved 2026-08-29 - In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Hepatic Impairment No studies have been performed with metoprolol succinate extended-release tablets in patients with hepatic impairment. Source: US FDA label for metoprolol (metoprolol succinate), section 'use in specific populations', retrieved 2026-08-29 PREGNANCY - Risk Summary Untreated hypertension and heart failure during pregnancy can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations). Source: US FDA label for metoprolol (metoprolol succinate), section 'pregnancy', retrieved 2026-08-29 - Available data from published observational studies have not demonstrated a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes with metoprolol use during pregnancy. Source: US FDA label for metoprolol (metoprolol succinate), section 'pregnancy', retrieved 2026-08-29 - However, there are inconsistent reports of intrauterine growth restriction, preterm birth, and perinatal mortality with maternal use of beta-blockers, including metoprolol, during pregnancy ( see Data ). Source: US FDA label for metoprolol (metoprolol succinate), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - Risk Summary Based on the published literature, beta-blockers (including metoprolol) may cause erectile dysfunction and inhibit sperm motility. Source: US FDA label for metoprolol (metoprolol succinate), section 'nursing mothers', retrieved 2026-08-29 - No evidence of impaired fertility due to metoprolol was observed in rats [see Nonclinical Toxicology (13.1) ]. Source: US FDA label for metoprolol (metoprolol succinate), section 'nursing mothers', retrieved 2026-08-29 - No fetal abnormalities were observed when pregnant rats received metoprolol orally up to a dose of 200 mg/kg/day, i.e., 10 times, the daily dose of 200 mg in a 60-kg patient. 8.2 Lactation Risk Summary Limited available data from published literature report that metoprolol is present in human milk. Source: US FDA label for metoprolol (metoprolol succinate), section 'use in specific populations', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)